Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 3/20 | 0.47 |
| ▸ | PPARG | P37231 | 3/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1874367 | 0.93 | ALDH1A1 (0.45) | NAAATSHRALDH1A1LMNA | |
| SCHEMBL1370842 | 0.85 | PPM1B (0.41) | TSHRALDH1A1LMNA | |
| SCHEMBL16104472 | 0.83 | PPARG (0.46) | NAAAPPARGEPHX1TSHRALDH1A1 | |
| SCHEMBL11835270 | 0.83 | PPARG (0.46) | NAAAPPARGEPHX1TSHRALDH1A1 | |
| SCHEMBL21494365 | 0.82 | NAAA (0.43) | NAAAPPARGEPHX1TSHRALDH1A1 | |
| SCHEMBL1296678 | 0.82 | NAAA (0.59) | NAAAPPARGEPHX1TSHRALDH1A1 | |
| SCHEMBL1296572 | 0.82 | NAAA (0.59) | NAAAPPARGEPHX1TSHRALDH1A1 | |
| SCHEMBL1298171 | 0.82 | NAAA (0.53) | NAAAPPARGEPHX1TSHRALDH1A1 | |
| SCHEMBL1297758 | 0.82 | NAAA (0.53) | NAAAPPARGEPHX1TSHRALDH1A1 | |
| SCHEMBL1297645 | 0.82 | NAAA (0.53) | NAAAPPARGEPHX1TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119684291-A | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | 艾科思莱德制药公司 | 2025-03-25 | — | — | CN | disclosed |
| US-12187742-B2 | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | XRAD THERAPEUTICS, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| EP-4003345-B1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRAD THERAPEUTICS INC (US) | 2024-12-04 | — | — | EP | disclosed |
| CN-114258301-B | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | 艾科思莱德制药公司 | 2024-11-08 | — | — | CN | disclosed |
| CN-112469720-B | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | 艾科思莱德制药公司 | 2024-03-29 | — | — | CN | disclosed |
| EP-4327877-A2 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRad Therapeutics, Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| EP-3784671-B1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRAD THERAPEUTICS INC (US) | 2023-10-11 | — | — | EP | disclosed |
| US-20220315606-A1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRAD HOLDING CAYMAN LIMITED (KY) | 2022-10-06 | — | — | US | disclosed |
| EP-4003345-A1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRad Therapeutics, Inc. (US) | 2022-06-01 | — | — | EP | disclosed |
| US-20220142995-A1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRAD HOLDING CAYMAN LIMITED (KY) | 2022-05-12 | — | — | US | disclosed |
| US-20220142995-A1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRAD HOLDING CAYMAN LIMITED (KY) | 2022-05-12 | — | — | US | disclosed |
| CN-114258301-A | Dual ATM and DNA-PK inhibitors for use in antitumor therapy | 艾科思莱德制药公司 | 2022-03-29 | — | — | CN | disclosed |
| CN-112469720-A | Dual ATM and DNA-PK inhibitors for use in antitumor therapy | 艾科思莱德制药公司 | 2021-03-09 | — | — | CN | disclosed |
| EP-3784671-A1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRad Therapeutics, Inc. (US) | 2021-03-03 | — | — | EP | disclosed |
| WO-2021022078-A1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRAD THERAPEUTICS, INC. (US) | 2021-02-04 | — | — | WO | disclosed |
| WO-2021022078-A1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRAD THERAPEUTICS, INC. (US) | 2021-02-04 | — | — | WO | disclosed |
| CN-112300159-A | Dual ATM and DNA-PK inhibitors for use in antitumor therapy | 艾科思莱德制药公司 | 2021-02-02 | — | — | CN | disclosed |
| WO-2019201283-A1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRAD THERAPEUTICS, INC. (US) | 2019-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315606-A1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | ATM, CHEK2, CHEK1 | NAAA 4351/4885PPARG 1499/4885EPHX1 4720/4885 |
| US-20220142995-A1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | ATM, CHEK2, CHEK1 | NAAA 4324/4885PPARG 1810/4885EPHX1 4708/4885 |
| US-12187742-B2 | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | ATM, CHEK2, CHEK1 | NAAA 4351/4885PPARG 1499/4885EPHX1 4720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.